The Th17 axis in psoriatic disease

Pathogenetic and therapeutic implications

Beatrice Marinoni, Angela Ceribelli, Marco S. Massarotti, Carlo Selmi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Psoriasis and psoriatic arthritis represent two paradigmatic conditions characterized by chronic inflammation and possibly autoimmunity, despite the absence of known serum autoantibodies. The two diseases, albeit strongly correlated from clinical, genetic, and epidemiogical standpoints, manifest significant differences in terms of etiology and pathogenetic mechanisms. Nonetheless, Th17 cells appear crucial to both diseases, and IL23 is the cytokine involved in determining the fate of naive CD4+ cells to differentiate into a pathogenic phenotype. This basic experimental observation led to a clear understanding of the immune dysfunction causing psoriasis and psoriatic arthritis but, more importantly, also led to new therapeutic approaches. In recent years, monoclonal antibodies directed to IL12/IL23 (ustekinumab) or IL17 (secukinumab, ixekizumab, brodalumab) are being investigated or have proven to be beneficial for patients with psoriatic disease, thus further supporting the view that Th17 cells play a pivotal role in disease onset and perpetuation. These most recent reports indeed represent significant developments that may allow overcoming the TNFα pathway as the major therapeutic target in chronic inflammation.

Original languageEnglish (US)
Pages (from-to)9-19
Number of pages11
JournalAutoimmunity Highlights
Volume5
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Th17 Cells
Psoriatic Arthritis
LY2439821
Psoriasis
Inflammation
Therapeutics
Interleukin-12
Autoimmunity
Autoantibodies
Monoclonal Antibodies
Observation
Cytokines
Phenotype
Serum
secukinumab
Ustekinumab
brodalumab

Keywords

  • IL12
  • IL17
  • IL23
  • Inflammation
  • Psoriasis
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

The Th17 axis in psoriatic disease : Pathogenetic and therapeutic implications. / Marinoni, Beatrice; Ceribelli, Angela; Massarotti, Marco S.; Selmi, Carlo.

In: Autoimmunity Highlights, Vol. 5, No. 1, 2014, p. 9-19.

Research output: Contribution to journalArticle

Marinoni, Beatrice ; Ceribelli, Angela ; Massarotti, Marco S. ; Selmi, Carlo. / The Th17 axis in psoriatic disease : Pathogenetic and therapeutic implications. In: Autoimmunity Highlights. 2014 ; Vol. 5, No. 1. pp. 9-19.
@article{b9d5c42c513f4151a1c9fe4f8f12a6c6,
title = "The Th17 axis in psoriatic disease: Pathogenetic and therapeutic implications",
abstract = "Psoriasis and psoriatic arthritis represent two paradigmatic conditions characterized by chronic inflammation and possibly autoimmunity, despite the absence of known serum autoantibodies. The two diseases, albeit strongly correlated from clinical, genetic, and epidemiogical standpoints, manifest significant differences in terms of etiology and pathogenetic mechanisms. Nonetheless, Th17 cells appear crucial to both diseases, and IL23 is the cytokine involved in determining the fate of naive CD4+ cells to differentiate into a pathogenic phenotype. This basic experimental observation led to a clear understanding of the immune dysfunction causing psoriasis and psoriatic arthritis but, more importantly, also led to new therapeutic approaches. In recent years, monoclonal antibodies directed to IL12/IL23 (ustekinumab) or IL17 (secukinumab, ixekizumab, brodalumab) are being investigated or have proven to be beneficial for patients with psoriatic disease, thus further supporting the view that Th17 cells play a pivotal role in disease onset and perpetuation. These most recent reports indeed represent significant developments that may allow overcoming the TNFα pathway as the major therapeutic target in chronic inflammation.",
keywords = "IL12, IL17, IL23, Inflammation, Psoriasis, Psoriatic arthritis",
author = "Beatrice Marinoni and Angela Ceribelli and Massarotti, {Marco S.} and Carlo Selmi",
year = "2014",
doi = "10.1007/s13317-013-0057-4",
language = "English (US)",
volume = "5",
pages = "9--19",
journal = "Autoimmunity Highlights",
issn = "2038-0305",
publisher = "Springer-Verlag Italia",
number = "1",

}

TY - JOUR

T1 - The Th17 axis in psoriatic disease

T2 - Pathogenetic and therapeutic implications

AU - Marinoni, Beatrice

AU - Ceribelli, Angela

AU - Massarotti, Marco S.

AU - Selmi, Carlo

PY - 2014

Y1 - 2014

N2 - Psoriasis and psoriatic arthritis represent two paradigmatic conditions characterized by chronic inflammation and possibly autoimmunity, despite the absence of known serum autoantibodies. The two diseases, albeit strongly correlated from clinical, genetic, and epidemiogical standpoints, manifest significant differences in terms of etiology and pathogenetic mechanisms. Nonetheless, Th17 cells appear crucial to both diseases, and IL23 is the cytokine involved in determining the fate of naive CD4+ cells to differentiate into a pathogenic phenotype. This basic experimental observation led to a clear understanding of the immune dysfunction causing psoriasis and psoriatic arthritis but, more importantly, also led to new therapeutic approaches. In recent years, monoclonal antibodies directed to IL12/IL23 (ustekinumab) or IL17 (secukinumab, ixekizumab, brodalumab) are being investigated or have proven to be beneficial for patients with psoriatic disease, thus further supporting the view that Th17 cells play a pivotal role in disease onset and perpetuation. These most recent reports indeed represent significant developments that may allow overcoming the TNFα pathway as the major therapeutic target in chronic inflammation.

AB - Psoriasis and psoriatic arthritis represent two paradigmatic conditions characterized by chronic inflammation and possibly autoimmunity, despite the absence of known serum autoantibodies. The two diseases, albeit strongly correlated from clinical, genetic, and epidemiogical standpoints, manifest significant differences in terms of etiology and pathogenetic mechanisms. Nonetheless, Th17 cells appear crucial to both diseases, and IL23 is the cytokine involved in determining the fate of naive CD4+ cells to differentiate into a pathogenic phenotype. This basic experimental observation led to a clear understanding of the immune dysfunction causing psoriasis and psoriatic arthritis but, more importantly, also led to new therapeutic approaches. In recent years, monoclonal antibodies directed to IL12/IL23 (ustekinumab) or IL17 (secukinumab, ixekizumab, brodalumab) are being investigated or have proven to be beneficial for patients with psoriatic disease, thus further supporting the view that Th17 cells play a pivotal role in disease onset and perpetuation. These most recent reports indeed represent significant developments that may allow overcoming the TNFα pathway as the major therapeutic target in chronic inflammation.

KW - IL12

KW - IL17

KW - IL23

KW - Inflammation

KW - Psoriasis

KW - Psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=84902960589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902960589&partnerID=8YFLogxK

U2 - 10.1007/s13317-013-0057-4

DO - 10.1007/s13317-013-0057-4

M3 - Article

VL - 5

SP - 9

EP - 19

JO - Autoimmunity Highlights

JF - Autoimmunity Highlights

SN - 2038-0305

IS - 1

ER -